MECHANISM OF ACTION
Both pregabalin and thiazolidinedione antidiabetics
may cause weight gain and/or fluid retention.(1)
DISCUSSION
In clinical trials, the incidence of peripheral edema was 3% of
patients receiving a thiazolidinedione antidiabetic alone, 8% of patients
receiving pregabalin alone, and 19% of patients on combination therapy. The
incidence of weight gain was 0% of patients receiving a thiazolidinedione
antidiabetic alone, 4% of patients receiving pregabalin alone, and 7.5% of
patients on combination therapy.(1)
CLINICAL EFFECTS
Concurrent use of pregabalin and thiazolidinedione
antidiabetics may result in weight gain and/or fluid retention, which may
increase the risk of heart failure in patients with preexisting cardiac
conditions.(1)
SEVERITY LEVEL
3-Moderate Interaction: Assess the risk to the patient and
take action as needed.
PATIENT MANAGEMENT
Patients should be monitored for weight gain and/or
fluid retention when taking pregabalin with the thiazolidinedione
antidiabetics agents together. Congestive heart failure or worsening of
existing congestive heart failure may occur.
PREDISPOSING FACTORS
Preexisting cardiac conditions may increase the risk
of heart failure.(1)
REFERENCE